Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC

Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC
Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. The European Commission’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) issued last May. It will make Lynparza available for women who are responding, partially or completely, to their initial platinum-based chemotherapy. The treatment had already been approved in the U.S. for a similar indication. “The goals of front-line therapy have always been long-term remission and even cure, yet currently 70% of patients relapse within three years of initial treatment,” Dave Fredrickson, executive vice president of oncology business at AstraZeneca, said in a press release. “This approval sets the stage for a new standard of care in the EU for women with ovarian cancer and a BRCA mutation.” Both U.S. and European approvals
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *